Clinical Trial Update: DHA and X-Linked Retinitis Pigmentosa [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated docosahexaenoic acid (DHA) for X-linked retinitis pigmentosa; results were posted after the study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• X-linked Retinitis Pigmentosa

Drugs mentioned

• Docosahexaenoic acid (DHA) (docosahexaenoic acid)

Snippet

Sponsor: Retina Foundation of the Southwest | Conditions: Retinitis Pigmentosa, X-linked Genetic Diseases | Phase 2 | Status: COMPLETED | Results posted: 2015-03-17